The drug discovery landscape is rapidly changing and with it comes the need to generate leads with lower attrition rate. Property-based drug design approach is guiding researchers in designing candidates with the right balance of physicochemical properties - safety and absorption, distribution, metabolism, and excretion (ADME) profiles. 4th Annual Property-Based Drug Design in Medicinal Chemistry conference will bring together experts and leaders from industry and academia to share strategies and case studies for new and non-traditional molecules, how computational modeling and data management can be used effectively, and to discuss novel ways to measure or predict properties to make molecules more drug-like and overcome challenges in discovery, development, and the clinic.
Preliminary Agenda | Speaker Biographies
Exploring Macrocycles for Drug Discovery: Novel Lead Series for Challenging Protein-Protein Interactions
Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.
Optimizing Brain Exposure in CNS Drug Discovery
Ruben Alvarez Sanchez, Ph.D., Head of Pharmaceutical Profiling, Drug Disposition and Safety, F. Hoffmann-La Roche
Inhalation by Design: Approaches towards Designing Drug Candidates for Lung Diseases
Peter Jones, Ph.D., Senior Principal Scientist, Medicinal Chemistry - Inflammation and Remodelling, Pfizer, Inc.
Utilizing Physiologically-Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development
Jan Wahlstrom, Ph.D., Director, Pharmacokinetics & Drug Metabolism, Amgen, Inc.
A Systems Pharmacokinetics Approach to the Optimization of Drug Properties to Help Maximize Therapeutic Index: On the Quantitative Prediction of Unbound Tissue Distribution and its Implication for Drug Design
Avijit Ghosh, Ph.D., Director, Mechanism-Based Drug Disposition Pharmacodynamics and Metabolism, Janssen R&D
The Discovery and Development of an HIV-1 Attachment Inhibitor Clinical Candidate
Kap-Sun Yeung, Ph.D., Principal Scientist, Discovery Chemistry, Pharmaceutical R&D, Bristol-Myers Squibb Co.
Physicochemical Properties and Property-Based Drug Design in Heptatobilliary Transport
Manthena Varma, Ph.D., Senior Principal Scientist, Pharmacokinetics Dynamics & Metabolism, Pfizer, Inc.
Physicochemical and Biomimetic Properties to Guide Lead Optimization
Klara Valko, Ph.D., DSc, FRSC, Senior Scientific Investigator, UK Analytical Chemistry, RD Platform Technology & Science, GSK
Oral Druggable Space Beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Jan Kihlberg, Ph.D., Professor, Department of Chemistry, BMC, Uppsala University, Sweden
Computational Modeling and in silico Predication of Drug Properties
Terry Richard Stouch, Ph.D., President, Science for Solutions, LLC
Phosphatidylcholine Affinity Chromatography and Link to Compound Promiscuity, Non-Specific Binding and Phospholipidosis Assessment
John Reilly, Ph.D., Senior Research Investigator, Global Discovery Chemistry, Novartis
For questions about the meeting, please contact:
Cambridge Healthtech Institute
For sponsorship and exhibit information, contact:
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431